Xbrane Biopharma Seeks to Initiate the Development of Keytruda and Darzalex Biosimilar
Shots:
- Xbrane initiates the development of 2 biosimilar products referencing Keytruda & Darzalex along with Xdivane (biosimilar referencing Opdivo)
- Keytruda is a PD1 inhibitor used for oncology & Darzalex is a CD38 inhibitor used for MM & light chain amyloidosis. These biosimilar candidates along with Xdivane form an oncology biosimilar portfolio addressing $199.7M of combined annual reference product sales which are expected to launch in 2028-2029 on expiry of respective patents
- The company plans to develop 1 new biosimilar candidate/yr. Xbrane expanded its high-yield protein expression platform into mammalian cells with the development of Xdivane, which lead to 5 recently approved patents
Ref: Xbrane | Image: Xbrane
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
